Haobin Chen, M.D., Ph.D.
Dr. Chen's research focuses on developing novel epigenetic therapies for small cell lung cancer. He is board certified in internal medicine and board certified in medical oncology.
1) lung cancer, 2) epigenetics, 3) molecular biology
Small cell lung cancer (SCLC) is a deadly disease and represents 12-15% of all lung cancers. Little progress has been made in its treatment over the past 30 years. Some obstacles against progress are limited systemic treatment options and rapid development of drug resistance. There is an unmet need to understand resistance mechanisms and to develop novel therapies for SCLC.
Gene expression is controlled by epigenetic machinery in cells. Epigenetic therapy targets critical epigenetic machinery in cancer cells to restore normal gene expression and to stop cancer growth. BET bromodomain proteins are emerging epigenetic targets. The use of small molecule inhibitors to target this family of proteins has generated many promising results in liquid tumors, but this approach has not been tested in solid tumors. One of the focuses of my research is to identify which SCLC patients will benefit from this novel epigenetic therapy. The other focus of my research is to uncover drug resistance mechanism in SCLC by using a genome-wide high throughput screening approach.
Selected Key Publications
Hypoxia and nickel inhibit histone demethylase JMJD1A and repress Spry2 expression in human bronchial epithelial BEAS-2B cells.Carcinogenesis. 31: 2136-2144, 2010. [ Journal Article ]
Nickel ions inhibit histone demethylase JMJD1A and DNA repair enzyme ABH2 by replacing the ferrous iron in the catalytic centers.J Biol Chem. 285: 7374-7383, 2010. [ Journal Article ]
- Mol Cell Biol. 26: 3728-3737, 2006. [ Journal Article ]
Hypoxic stress induces dimethylated histone H3 lysine 9 through histone methyltranferase G9a in mammalian cells.Cancer Res. 66: 9009-9016, 2006. [ Journal Article ]
Nickel decreases cellular iron level and converts cytosolic aconitase to iron-regulatory protein 1 in A549 cells.Toxicol Appl Pharmacol. 206: 275-287, 2005. [ Journal Article ]
Dr. Chen received his M.D. and M.S. from Shanghai Medical University in China, and his Ph.D. degree from New York University (NYU). He was a research assistant professor at NYU for 4 years, and then completed an internal medicine residency at the Kingsbrook Jewish Medical Center in Brooklyn, NY. He joined the NCI Medical Oncology Branch as a clinical fellow in 2013. He is currently an assistant clinical investigator in the Thoracic and Gastrointestinal Oncology Branch.
|Anju Kumari||Predoctoral Visting Fellow (Graduate Student)|